Skip to main
EKSO

EKSO Stock Forecast & Price Target

EKSO Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ekso Bionics Holdings Inc experienced a notable recovery in its financial performance during the third quarter of 2025, reporting total revenues of $4.22 million, which reflects a 105% quarter-over-quarter increase from $2.06 million in the second quarter. Additionally, the company's gross margins improved significantly to 60.3%, up from 39.8% in the previous quarter, indicating enhanced profitability amid sales growth. Furthermore, the recent non-binding merger agreement with Applied Digital Cloud indicates a strategic move that could bolster Ekso's market position and drive future growth opportunities.

Bears say

Ekso Bionics Holdings experienced a revenue shortfall relative to consensus expectations, primarily attributed to two order delays in enterprise sales amounting to $1.5 million, indicating challenges in maintaining operational momentum. In the third quarter of 2025, the company reported revenues of $4.23 million, slightly exceeding the consensus estimate of $4.16 million; however, it still suffered a significant net loss of $0.54 per share. The downgrading of the stock to a neutral rating reflects underlying concerns about the company's growth trajectory and operational effectiveness, despite modest revenue improvements.

EKSO has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ekso Bionics Hlds (EKSO) Forecast

Analysts have given EKSO a Strong Buy based on their latest research and market trends.

According to 2 analysts, EKSO has a Strong Buy consensus rating as of Jan 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ekso Bionics Hlds (EKSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.